/content/dam/www/people-profile-photos/s/bart-scott/provider-bart-scott-directory-1x.jpg
/content/dam/www/people-profile-photos/s/bart-scott/provider-bart-scott-directory-2x.jpg
Scott
Bart L. Scott, MD

Bart L. Scott, MD

Medical Oncology

  • Physician, Fred Hutch
  • Professor, Transplantation Program, Clinical Research Division, Fred Hutch
  • Miklos Kohary and Natalia Zimonyi Kohary Endowed Chair, Fred Hutch
  • Professor, Division of Hematology and Oncology, University of Washington School of Medicine
Request an Appointment

About

Dr. Bart L. Scott is a board-certified medical oncologist and researcher at Fred Hutch. He treats myelodysplastic syndromes and myeloproliferative neoplasms and leads clinical research to improve blood cancer treatments, including stem cell transplant approaches.

Background

Dr. Scott is the director of hematology and hematologic malignancies at Fred Hutch and focuses on both patient care and research. He specializes in treating myelodysplastic syndromes (MDS). Sometimes referred to as “preleukemia,” MDS refers to a group of disorders in which the bone marrow fails to produce enough healthy blood cells. Treatment for MDS is improving rapidly due to clinical trials, and Dr. Scott is developing multiple treatment protocols for this disease, which affects thousands of people in the U.S. each year. Alongside his research efforts, he emphasizes day‑to‑day patient interactions and received the 2016 Ali Al‑Johani Award for excellence in patient care.

Dr. Scott also specializes in myeloproliferative neoplasms (MPN), a rare group of blood cancers caused by overproduction of red blood cells, white blood cells or platelets. He coordinates care for patients with MPN from around the world and conducts clinical trials of new drug therapies, including pacritinib. His research looks at the genetic mutations that drive MPN to support the development of more targeted treatments with fewer side effects. In addition, Dr. Scott studies ways to improve treatment strategies for patients with MDS and MPN, including new combinations of conditioning regimens used before blood stem cell transplantation.

Area of Clinical Practice
Adult blood and marrow transplantation, cellular immunotherapy, hematologic malignancies

“I know your disease and the latest treatments, but only you can guide me to meet your health needs.”

— Dr. Scott

What is your personal experience with cancer?

Cancer survivor, family member of a patient, physician — I’ve been all three. When I was in high school, my mom was diagnosed with breast cancer. After watching her go through what she did and seeing the doctors work with her, I knew that I wanted to be a doctor, too. Then, in my second year of medical school, I was diagnosed with Hodgkin lymphoma. That’s when I learned firsthand about the benefits of people participating in clinical trials. Thanks to those patients, I survived a disease that once had a high mortality rate. These experiences have made me more aware of what patients and families go through when cancer barges into their lives.

What do you want patients to know about clinical trials?

There’s often a misconception that participating in a clinical trial means you won’t get the best treatment. Actually, the opposite is true. Those who decide to join a trial tend to get far superior treatment compared to those who don’t. One reason is the level of monitoring: A team of experts in your particular disease will oversee your care very closely. Another reason is that you have access to the very latest therapies available, which may be more effective than conventional methods. There are no placebos. In the end, you have to decide what’s right for you, and clinical trials aren’t without risk. But choosing to participate in one means that you have the chance to help future patients while also helping yourself.

Diseases Treated

Acute Myeloid Leukemia

Aplastic Anemia

Blood Disorders

Chronic Myeloid Leukemia

Essential Thrombocytosis

Leukemia

Myelodysplastic Syndrome

Myelomonocytic Leukemia

Myeloproliferative Neoplasms

Polycythemia Vera

Research Interests

Clinical trials for myelodysplastic syndrome and myeloproliferative disorders

Languages

English

Education and Experience

Fellowship, University of Washington, Hematology-Oncology

Residency, Johns Hopkins University, School of Medicine

MD, University of South Alabama-Mobile, School of Medicine

BS, Biology and Chemistry, University of Alabama at Birmingham

Board Certification

Medical Oncology, 2003, 2019, American Board of Internal Medicine

 

Clinical Trials

We make promising new treatments available to you through studies called clinical trials led by Fred Hutch physicians. Many of these trials at Fred Hutch have led to FDA-approved treatments and have improved standards of care globally. Together, you and your physician can decide if a study is right for you. 

Find a Clinical Trial Led by Dr. Scott

Publications

Many of our Fred Hutch physicians conduct ongoing research to improve standards of patient care. Their work is evaluated by other physicians and selected for publication to the United States National Library of Medicine, the largest medical library in the world. See scientific papers this Fred Hutch physician has written. 

View Dr. Scott's Publications

Your Care Team

At Fred Hutch, you receive care from a team of providers with extensive experience in your disease. Your team includes physicians, a patient care coordinator, a registered nurse, an advanced practice provider and others, based on your needs. You also have access to experts like registered dietitians, social workers, acupuncturists, psychiatrists and more who specialize in supporting people with cancer or blood disorders. 

Meet Other Providers

Insurance

Fred Hutch accepts most national private health insurance plans as well as Medicare. We also accept Medicaid for people from Washington, Alaska, Montana and Idaho. We are working to ensure that everyone, no matter what their financial situation, has access to the care they need.

More About Insurance

Stories

All news
Dr. Bart Scott named Miklos Kohary and Natalia Zimonyi Kohary Endowed Chair
Dr. Bart Scott named Miklos Kohary and Natalia Zimonyi Kohary Endowed Chair Chair recognizes a quarter-century of commitment to advancing MDS treatment and the opportunities ahead May 8, 2024
Alec Hill
Alec Hill January 1, 2018
Why some patients keep their cancer secret — and how oncologists guide them through that chosen seclusion
Why some patients keep their cancer secret — and how oncologists guide them through that chosen seclusion Why some patients don’t divulge their diagnoses — and how oncologists guide them through their chosen seclusion August 29, 2016

Contact Information

206.667.1990

206.667.6124